Drug Discovery News and Research

RSS
The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.
Purdue researcher receives $2.4 million NIH grant to combat antimicrobial resistance in lung infections

Purdue researcher receives $2.4 million NIH grant to combat antimicrobial resistance in lung infections

UC San Diego's open source AI platform revolutionizes multi-target drug discovery

UC San Diego's open source AI platform revolutionizes multi-target drug discovery

Lab to plant: Scaling up API processes with Dr. James Mencel's guidance

Lab to plant: Scaling up API processes with Dr. James Mencel's guidance

Genomics plc and GSK collaborate to harness polygenic risk scores in clinical trials

Genomics plc and GSK collaborate to harness polygenic risk scores in clinical trials

Simple blood test could allow doctors to determine a person’s risk for stroke or cognitive decline

Simple blood test could allow doctors to determine a person’s risk for stroke or cognitive decline

Nuclera eProtein Discovery system installed at leading academic institutes

Nuclera eProtein Discovery system installed at leading academic institutes

ELRIG UK announces Profs Ijeoma Uchegbu and Marcus Schindler as keynote speakers at Drug Discovery 2024

ELRIG UK announces Profs Ijeoma Uchegbu and Marcus Schindler as keynote speakers at Drug Discovery 2024

Insilico Medicine's AI-designed drug ISM3412 receives FDA IND approval

Insilico Medicine's AI-designed drug ISM3412 receives FDA IND approval

CN Bio raises $21 million USD in first close of Series B investment round

CN Bio raises $21 million USD in first close of Series B investment round

Neurolentech signs technology access partnership with Kaerus Bioscience to advance neurodevelopmental disorder research

Neurolentech signs technology access partnership with Kaerus Bioscience to advance neurodevelopmental disorder research

First-of-its-kind AI tool predicts patient response to cancer drugs at single-cell resolution

First-of-its-kind AI tool predicts patient response to cancer drugs at single-cell resolution

Salk scientists explain how CBN protects the brain against aging and neurodegeneration

Salk scientists explain how CBN protects the brain against aging and neurodegeneration

AI techniques massively accelerate the search for Parkinson's disease treatments

AI techniques massively accelerate the search for Parkinson's disease treatments

ELRIG UK and SRG announce partnership to advance life science professionals in drug discovery

ELRIG UK and SRG announce partnership to advance life science professionals in drug discovery

MD Anderson and CureVac collaborate on mRNA-based cancer vaccines

MD Anderson and CureVac collaborate on mRNA-based cancer vaccines

Deciphering the molecular interactions of opioid receptors: Implications for drug design

Deciphering the molecular interactions of opioid receptors: Implications for drug design

Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy

Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy

Blocking polyphosphates could help treat chronic infections

Blocking polyphosphates could help treat chronic infections

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.